T-regulatory cell treatment prevents chronic rejection of heart allografts in a murine mixed chimerism model

详细信息    查看全文

• 作者：Nina Pilat ; PhD^a ; Andreas M. Farkas ; MSc^a ; Benedikt Mahr ; MSc^a ; Christoph Schwarz ; MD^a ; Lukas Unger^a ; Karin Hock ; PhD^a ; Rupert Oberhuber ; MD^b ; Klaus Aumayr ; MD^c ; Fritz Wrba ; MD^c ; Thomas Wekerle ; MD^a ; ^{thomas.wekerle@meduniwien.ac.at" class="auth_mail}
• 关键词：mixed chimerism ; tolerance ; regulatory T cells ; chronic rejection ; heart transplantation ; costimulation blockade
• 刊名：The Journal of Heart and Lung Transplantation
• 出版年：April, 2014
• 年：2014
• 卷：33
• 期：4
• 页码：429-437
• 全文大小：5042 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Background

The mixed chimerism approach induces donor-specific tolerance in both pre-clinical models and clinical pilot trials. However, chronic rejection of heart allografts and acute rejection of skin allografts were observed in some chimeric animals despite persistent hematopoietic chimerism and tolerance toward donor antigens in vitro. We tested whether additional cell therapy with regulatory T cells (Tregs) is able to induce full immunologic tolerance and prevent chronic rejection.

Methods

We recently developed a murine 鈥淭reg bone marrow (BM) transplantation (BMT) protocol鈥?that is devoid of cytoreductive recipient pre-treatment. The protocol consists of a moderate dose of fully mismatched allogeneic donor BM under costimulation blockade, together with polyclonal recipient Tregs and rapamycin. Control groups received BMT under non-myeloablative irradiation and costimulation blockade without Treg therapy. Multilineage chimerism was followed by flow cytometry, and tolerance was assessed by donor-specific skin and heart allografts.

Results

Durable multilineage chimerism and long-term donor skin and heart allograft survival were successfully achieved with both protocols. Notably, histologic examination of heart allografts at the end of follow-up revealed that chronic rejection is prevented only in chimeras induced with the Treg protocol.

Conclusions

In a mouse model of mixed chimerism, additional Treg treatment at the time of BMT prevents chronic rejection of heart allografts. As the Treg-chimerism protocol also obviates the need for cytoreductive recipient treatment it improves both efficacy and safety over previous non-myeloablative mixed chimerism regimens. These results may significantly impact the development of protocols for tolerance induction in cardiac transplantation.